Liquid biopsies come of age: towards implementation of circulating tumour DNA

  title={Liquid biopsies come of age: towards implementation of circulating tumour DNA},
  author={Jonathan C M Wan and Charles E Massie and Javier Garcia-Corbacho and Florent Mouliere and James D. Brenton and Carlos Caldas and Simon C Pacey and Richard D. Baird and Nitzan Rosenfeld},
  journal={Nature Reviews Cancer},
Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy' for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and monitoring. The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn… 
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
The authors discuss the current role of plasma ctDNA assays in oncology care and provide an overview of ongoing research that may inform real‐world clinical applications in the near future.
Cell-free DNA in cancer: current insights
The biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer are discussed, and important challenges and future directions for the integration of cTDNA into standardised patient care are highlighted.
Circulating tumor DNA and liquid biopsy in oncology.
The full potential of ctDNA liquid biopsy in the diagnosis, characterization and management of solid and hematological malignancies will be uncovered through interventional clinical trials evaluating clinical utility.
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
The literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies is reviewed and new directions for future studies are suggested.
Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements
The most relevant studies on ctDNA analysis in cancer, as well as the future directions and applications of liquid biopsy are discussed, with special attention paid to the early diagnosis of primary cancer, to the diagnosis of tumors with an unknown primary location, and finally to the prognosis of cancer patients.
ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status
Liquid biopsy using circulating tumor DNA (ctDNA) has, in recent years, become a minimally invasive tool to provide valuable molecular information in a dynamic fashion for clinical decision-making in CRC.
Circulating Tumour DNA in Muscle-Invasive Bladder Cancer
An overview of work to date on ctDNA in MIBC is presented, and the inherent challenges present as well as the potential future clinical applications are discussed.
The potential of liquid biopsies for the early detection of cancer
Biology, technical complexities and clinical significance for early cancer detection and their impact on precision oncology are discussed.
Circulating tumor DNA: Where are we now? A mini review of the literature
The process of liquid biopsy allows for a minimally invasive procedure that provides molecular information about underlying cancer by analyzing circulating tumor DNA via next-generation sequencing technology and circulating tumor cells.


Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
This review focuses on key areas of clinical applications of CTCs and ctDNA, including detection of cancer, prediction of prognosis in patients with curable disease, monitoring systemic therapies, and stratification of patients based on the detection of therapeutic targets or resistance mechanisms.
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
Assessment of ctDNA is a non-invasive, exquisitely specific and highly sensitive approach for monitoring disease load, which has the potential to provide clinically relevant lead times compared with conventional methods.
Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
This initial study demonstrates that ctDNA tests provide information complementary to that in tissue biopsies and may be useful in determining prognosis and treatment.
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
It is demonstrated that ctDNA is correlated with volume of disease at the start of treatment in women with HGSOC and that a decrease of ≤60% in TP53MAF after one cycle of chemotherapy was associated with shorter TTP, and warrants further investigation in larger cohorts receiving uniform treatment.
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
  • J. Tie, I. Kinde, P. Gibbs
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
Early changes in ctDNA during first-line chemotherapy predict the later radiologic response and is detectable in a high proportion of treatment naïve mCRC patients.
Digital PCR-based technologies used to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types suggest that ctDNA is a sensitive, specific and robust biomarker that can be used for a variety of clinical and research purposes in patients with several multiple different types of cancer.
Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA
It is shown that ctDNA may be useful biomarker for monitoring tumor growth and treatment response and confirmed that high levels of cell-free DNA are found in cancer patients compared to healthy individuals.
Circulating mutant DNA to assess tumor dynamics
It is found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy, and it is suggested that this personalized genetic approach could be generally applied to individuals with other types of cancer.